Frazier Life Sciences Management’s Aclaris Therapeutics ACRS Stock Holding History

Frazier Life Sciences Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.1M	Hold	4,925,374	–	–	0.57%	29
2026 Q1	$18.5M	Buy	+4,925,374	New	+$16.6M	0.48%	28
2024 Q4	–	Sell	-264,377	Closed	-$304K	–	51
2024 Q3	$304K	Hold	264,377	–	–	0.01%	52
2024 Q2	$291K	Hold	264,377	–	–	0.01%	49
2024 Q1	$328K	Hold	264,377	–	–	0.01%	50
2023 Q4	$278K	Hold	264,377	–	–	0.01%	49
2023 Q3	$1.81M	Hold	264,377	–	–	0.12%	48
2023 Q2	$2.74M	Hold	264,377	–	–	0.16%	46
2023 Q1	$2.14M	Sell	264,377 -25,812	-9%	-$328K	0.15%	47
2022 Q4	$4.57M	Sell	290,189 -118,140	-29%	-$1.9M	0.28%	40
2022 Q3	$6.43M	Hold	408,329	–	–	0.49%	35
2022 Q2	$5.7M	Hold	408,329	–	–	0.54%	31
2022 Q1	$7.04M	Buy	+408,329	New	+$5.57M	0.6%	33

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Frazier Life Sciences Management's ACRS Position: Q2 2026 in Review

Frazier Life Sciences Management held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 4,925,374 shares worth $26.1M. The position accounts for 0.57% of the portfolio, ranked #29.

Frazier Life Sciences Management first reported a position in ACRS in Q1 2022 and has held it in 13 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Frazier Life Sciences Management held 4,925,374 shares of Aclaris Therapeutics worth $26.1M as of Q2 2026.
Frazier Life Sciences Management left its Aclaris Therapeutics share count unchanged in Q2 2026.
Aclaris Therapeutics made up 0.57% of Frazier Life Sciences Management's portfolio in Q2 2026, its #29 holding.
Frazier Life Sciences Management first reported a position in Aclaris Therapeutics in Q1 2022 and has held it in 13 quarters since.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.